Prosecution Insights
Last updated: April 19, 2026

Examiner: WHEELER, THURMAN MICHAEL

Tech Center 1600 • Art Units: 1619

This examiner grants 46% of resolved cases

Performance Statistics

45.6%
Allow Rate
-14.4% vs TC avg
653
Total Applications
+23.4%
Interview Lift
1483
Avg Prosecution Days
Based on 608 resolved cases, 2023–2026

Rejection Statute Breakdown

0.5%
§101 Eligibility
8.9%
§102 Novelty
52.1%
§103 Obviousness
22.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16623591 COSMETIC COMPOSITION COMPRISING TWO SPECIFIC CATIONIC SURFACTANTS AND A SILICONE EMULSION, AND A COSMETIC TREATMENT PROCESS Non-Final OA L'OREAL
17535062 PHENYLALANINE FUNCTIONALISED MESOPOROUS SILICA NANOPARTICLES AS DRUG-FREE NANOTHERAPEUTICS OR BIOACTIVE NANOCARRIER FOR ANTI-CANCER APPLICATIONS Final Rejection Nanyang Technological University
17862959 SHEAR-THINNING COMPOSITIONS AS AN INTRAVASCULAR EMBOLIC AGENT Non-Final OA The General Hospital Corporation
18332101 NON-VIRAL DELIVERY OF SMALL MOLECULE THERAPEUTICS Final Rejection BATTELLE MEMORIAL INSTITUTE
17790805 NITRAPYRIN COMPOSITIONS FOR ENHANCING NITROGEN NUTRIENT USE EFFICIENCY AND IMPROVING PLANT GROWTH Final Rejection Verdesian Life Sciences U.S., LLC
18784354 TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER WITH A THERMALLY GELLING PHARMACEUTICAL COMPOSITION CONTAINING MITOMYCIN Non-Final OA UROGEN PHARMA LTD.
17713871 FABRIC COMPOSITIONS COMPRISING ATTACHED ASCORBIC ACID Final Rejection Virginia Commonwealth University
17967267 Microemulsion Delivery Systems for A Female Hormone Blend with Alcohol-Soluble Species Including Nonderivatized Hormones Non-Final OA Quicksilver Scientific, Inc.
17672894 Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones Non-Final OA Quicksilver Scientific, Inc.
16785549 SEMI-PERMANENT TATTOOS Non-Final OA inkbox ink incorporated
18496799 PROTEIN FUNCTIONALIZED HYALURONIC ACID COATED CHITOSAN NANOPARTICLE AND METHOD OF PREPARATION Final Rejection KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY
18361070 Phytic Acid Ester Derivative Final Rejection SCIENCE FARM LTD.
17404941 COMPOSITIONS AND METHODS TO DISINFECT, TREAT AND PREVENT MICROBIAL INFECTIONS Final Rejection WIAB WATER INNOVATION AB
17369620 COMPOSITIONS AND METHODS TO DISINFECT, TREAT AND PREVENT MICROBIAL INFECTIONS Non-Final OA WIAB WATER INNOVATION AB
18040436 ANTIBIOTIC THERAPEUTICS AND USES THEREOF Final Rejection GENTAGEL LR LTD.
17677295 COMPOSITIONS AND METHODS FOR SUSTAINED DRUG RELEASE FROM AN INJECTABLE HYDROGEL Final Rejection Contraline, Inc.
17589639 COMPOSITIONS AND METHODS FOR SUSTAINED TREATMENT OF PAIN Non-Final OA InSitu Biologics, Inc.
17937564 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Final Rejection Ascendis Pharma Ophthalmology Division A/S
17589422 ETHYL CELLULOSE BASED COATINGS FOR MICROENCAPSULATION OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS, AND NICOTINYL RIBOSIDE COMPOUND DERIVATIVES Final Rejection ChromaDex Inc.
17456469 POLYMERIC NANOPARTICLES AND A PROCESS OF PREPARATION THEREOF Non-Final OA Gravitas Life Sciences, Inc.
17408945 Low-Dose Doxepin Formulations And Methods Of Making And Using The Same Non-Final OA Currax Pharmaceuticals LLC
17345059 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM-CONTAINING ANTIMICROBIAL COMPOSITIONS AND USES THEREOF Non-Final OA Virox Technologies Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month